Meeder Asset Management Inc Chimerix Inc Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$5.23 - $7.18 $24,544 - $33,695	-4,693 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$5.94 - $8.75 $451 - $665	-76 Reduced 1.59%	4,693 $28,000
Q1 2021 Apr 28, 2021	BUY	$4.76 - $11.25 $22,700 - $53,651	4,769 New	4,769 $45,000
Q2 2020 Aug 11, 2020	SELL	$1.33 - $3.63 $2,661 - $7,263	-2,001 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$1.3 - $2.72 $30,248 - $63,288	-23,268 Reduced 92.08%	2,001 $4,000
Q3 2019 Oct 17, 2019	BUY	$1.93 - $4.21 $36,243 - $79,059	18,779 Added 289.35%	25,269 $60,000
Q2 2019 Aug 05, 2019	BUY	$2.05 - $4.32 $4,491 - $9,465	2,191 Added 50.97%	6,490 $27,000
Q1 2019 Apr 16, 2019	SELL	$1.79 - $3.12 $5,574 - $9,715	-3,114 Reduced 42.01%	4,299 $9,000
Q4 2018 Jan 17, 2019	BUY	$2.24 - $3.9 $16,605 - $28,910	7,413 New	7,413 $19,000
Q2 2018 Jul 24, 2018	SELL	$4.43 - $5.14 $4,678 - $5,427	-1,056 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$4.65 - $5.9 $4,533 - $5,752	975 Added 1203.7%	1,056 $5,000
Q4 2017 Feb 02, 2018	BUY	$4.32 - $5.52 $349 - $447	81	81 $0

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.